Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of MIZUHO MEDY CO.,LTD.. A complete text table follows the diagram.
COVID tests still lead revenue, but the next portfolio is broader: influenza, respiratory infections, molecular diagnostics and stable OTC demand.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| COVID-19 tests | 1 | 2.2B | 55.1% of reported total |
| Influenza tests | 1 | 296M | 7.4% of reported total |
| Other infection tests & equipment | 1 | 1.3B | 32.9% of reported total |
| OTC and other | 1 | 179M | 4.5% of reported total |
| Other & rounding | 1 | 2M | 0.1% of reported total |
| Revenue | 2 | 4.0B | JPY3.976B interim revenue |
| Diagnostic and OTC portfolio | 3 | 4.0B | COVID, influenza, other infection tests and consumer testing products |
| Other & rounding | 3 | 2M | The disclosed market categories total JPY3.974B; the JPY2M difference to reported net sales is retained as an explicit reconciliation. |
| From | To | Value |
|---|---|---|
| COVID-19 tests | Revenue | 2.2B |
| Influenza tests | Revenue | 296M |
| Other infection tests & equipment | Revenue | 1.3B |
| OTC and other | Revenue | 179M |
| Other & rounding | Revenue | 2M |
| Revenue | Diagnostic and OTC portfolio | 4.0B |
| Revenue | Other & rounding | 2M |